PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Company Overview - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through its proprietary PLEX technology, which allows for controlled, prolonged-release of therapeutics [3] - The company is preparing for the New Drug Application (NDA) submission of its lead product candidate, D-PLEX₁₀₀, aimed at preventing abdominal colorectal surgical site infections, expected in early 2026 [3] Upcoming Events - Senior management of PolyPid will participate in the 27th Annual H.C. Wainwright Global Investment Conference on September 8-9, 2025, in New York City [1] - A fireside chat with H.C. Wainwright Managing Director, Brandon Folkes, is scheduled for September 8, 2025, from 11:30 AM to 12:00 PM ET [2] - The management team will engage in both virtual and in-person one-on-one investor meetings during the conference [2]